



## **Representatives of Fulgent Genetics to Participate in the Piper Jaffray 29th Annual Healthcare Conference**

November 14, 2017

TEMPLE CITY, Calif., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent Genetics" or the "company") today announced that its Chairman and Chief Executive Officer Ming Hsieh and its Chief Financial Officer Paul Kim are scheduled to participate in the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017 at the Lotte New York Palace Hotel in New York, New York.

These representatives of the company will participate in a question-and-answer session with the host analyst beginning at approximately 8:00 a.m. ET.

A live webcast of the question and answer session will be available on the Investor Relations section of the Fulgent Genetics website at [ir.fulgentgenetics.com](http://ir.fulgentgenetics.com). A replay of the webcast will be accessible at [ir.fulgentgenetics.com](http://ir.fulgentgenetics.com) beginning approximately one hour following the completion of the event.

### **About Fulgent Genetics**

Fulgent Genetics is a growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu, which includes approximately 18,000 single-gene tests and more than 850 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today's market, which enables it to provide expansive options for test customization and clinically actionable results.

### **Investor Relations Contacts:**

The Blueshirt Group  
Nicole Borsje, 415-217-2633, [nborsje@blueshirtgroup.com](mailto:nborsje@blueshirtgroup.com)

Fulgent Genetics, Inc.